A clinical geneticist is discussing screening and prophylactic strategies with several women who have strong family histories of malignancy. For each described genetic mutation and associated gynecologic cancer risk profile, identify the correct corresponding hereditary syndrome.
- Autosomal dominant mutation in DNA mismatch repair genes (e.g., MSH2, MLH1) conferring a 40-60% lifetime risk of endometrial cancer as well as an increased risk of ovarian cancer.Lynch syndrome
- Autosomal dominant mutation in a tumor suppressor gene on chromosome 17q21 conferring a 40-50% lifetime risk of high-grade serous ovarian cancer.BRCA1-associated hereditary syndrome
- Autosomal dominant mutation in a tumor suppressor gene on chromosome 13q12 conferring a 15-20% lifetime risk of ovarian cancer, notably associated with male breast cancer in the family tree.BRCA2-associated hereditary syndrome
- Autosomal dominant mutation in the PTEN gene characterized by macrocephaly, mucocutaneous lesions, and an elevated risk of early-onset endometrial cancer.Cowden syndrome
- Autosomal dominant mutation in the STK11 gene manifesting with gastrointestinal polyposis, perioral lentigines, and a specific risk for ovarian sex cord tumors with annular tubules.Peutz-Jeghers syndrome
Answer
The genetic mutation profiles correctly pair with their respective hereditary syndromes based on the specific genes involved (mismatch repair, BRCA1/2, PTEN, STK11) and their distinct pattern of gynecologic and extragynecologic malignancies.
Gynecologic malignancies are frequently associated with specific germline mutations. Recognizing the extragynecologic manifestations and the specific genes involved (such as mismatch repair genes in Lynch syndrome, PTEN in Cowden syndrome, and STK11 in Peutz-Jeghers syndrome) is essential for identifying these hereditary syndromes and initiating appropriate screening and prophylactic surgical interventions.
Step-by-Step Solution
Key Concept
Hereditary Cancer Syndromes in Gynecologic Oncology